SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0001387131-21-005159
Filing Date
2021-04-30
Accepted
2021-04-30 16:50:40
Documents
5
Period of Report
2020-12-31

Document Format Files

Seq Description Document Type Size
1 AMENDED 10-K admp-10ka_123120.htm 10-K/A 592175
2 CERTIFICATION BY CEO PURSUANT TO SECTION 302 ex31-1.htm EX-31.1 16719
3 CERTIFICATION BY CFO PURSUANT TO SECTION 302 ex31-2.htm EX-31.2 17031
4 CERTIFICATION BY CEO PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 ex32-1.htm EX-32.1 7313
5 CERTIFICATION BY CFO PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 ex32-2.htm EX-32.2 7018
  Complete submission text file 0001387131-21-005159.txt   641392
Mailing Address 11682 EL CAMINO REAL SUITE 300 SAN DIEGO CA 92130
Business Address 11682 EL CAMINO REAL SUITE 300 SAN DIEGO CA 92130 (858) 997-2400
Adamis Pharmaceuticals Corp (Filer) CIK: 0000887247 (see all company filings)

IRS No.: 820429727 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K/A | Act: 34 | File No.: 001-36242 | Film No.: 21879099
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences